Columbus, OH

Researchers have discovered a new pathway used by cancer cells to infiltrate the brain and developed a promising therapy that targets this pathway with CAR T cells. Their study showed significant preclinical success in increasing survival and eradicating tumors in animal models of glioblastoma and other brain cancers. A team...

Brain Cancer Breakthrough: New Therapy Destroys Glioblastoma in Recently Unveiled Pathway

Axios Raleigh

Brain cancer research by a Duke scientist who's spent more than six decades at the university helped a drug receive FDA approval this week. Why it matters: The approval is the first major advancement in low-grade brain cancer treatment in more than two decades, according to the news outlet Fierce Pharma. Driving the news: The drug, called Voranigo, is the result of collaborative research by 83-year-old Duke physician-scientist Darell Bigner and Bert Vogelstein of Johns Hopkins. Voranigo is the seventh drug now on the market that has roots in Duke intellectual property, according to Robin Rasor, the school's associate vice...

An 83-year-old Duke professor's breakthrough research leads to new brain cancer drug

The fight against cancer is an arms race, and one of the most effective weapons in clinicians’ arsenals is immunotherapy. Immune checkpoint therapy has become the standard for treating several types of cancer. However, the Nobel Prize-winning strategy is ineffective for most pancreatic ductal adenocarcinoma (PDAC) patients. “Immune checkpoint...

Old chemo drug, new pancreatic cancer therapy?

Toni English’s medical team was giddy. It was six weeks after English had completed an experimental cancer treatment, and she had arrived at the Orlando Health Cancer Institute in Florida with her husband to see the results of her latest scan. Her team gathered in a patient exam room...

A newly approved ‘living drug’ could save more cancer patients’ lives

Eric Kumar Singhi, MD, discusses potential areas of research interest in the treatment of patients with metastatic lung cancer. Eric Kumar Singhi, MD, assistant professor, Department of General Oncology, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses potential areas of research interest in the treatment of patients with metastatic lung cancer.

Dr Singhi on Areas of Interest in Metastatic Lung Cancer Research

Bayer and biotechnology company NextRNA Therapeutics on Wednesday said they have partnered to develop a new kind of small molecule drug for cancer, agreeing to a collaboration deal that could be worth more than half of a billion dollars. The two companies will use NextRNA’s technology to advance two small...

Bayer partners with RNA drugmaker to develop new cancer therapies

Interesting Engineering

Janusz Racz, a 67-year-old lung cancer patient, is the first to receive this groundbreaking vaccine.

67-year-old receives world-first lung cancer vaccine as human trials begin

Community Voices represent independent, third-party users who have joined our contributor program but not yet verified their accounts. Community Voices are expected, like all users, to adhere to our Community Standards.

community_voice

Total Apex Sports & Entertainment

What makes today’s date special for your zodiac sign? Today, all zodiac signs are set to experience extraordinary cosmic shifts that would likely affect certain areas of their lives. For some signs, today’s cosmic boost will positively affect their finances. The planets have aligned to bring luck and good fortune their way. Hence, some individuals will feel a special wave of optimism and passion to lay a good foundation for financial abundance.

3 Lucky Zodiac Signs With Financial Abundance | August 22, 2024

Seattle, WA

Cancer Health

Lawrence Fong, MD’s research has focused on immunotherapy for more than 30 years. For many of those years, the new scientific director of the Immunotherapy Integrated Research Center at Fred Hutch Cancer Center considered immunotherapy — the practice of harnessing the body’s own immune system to fight cancer and other diseases — an idea whose time had not yet come.

How Immunotherapy Has Transformed Oncology

Parade

Oncologists explain the risk factors and how it's treated.

Here’s What Endometrial Cancer Actually Is—and How To Know if You’re at Risk for It

A collaborative study conducted by Duke-NUS and the NUS Mechanobiology Institute brings new hope for treating neurodevelopmental disorders by reactivating dormant neural stem cells and revealing additional mechanisms involved in brain development. Researchers at Duke-NUS Medical School and the Mechanobiology Institute at the National University of Singapore have identified a...

Breakthrough Discovery Awakens Dormant Brain Cells, Offering New Hope for Autism and Cerebral Palsy

The US Sun

A SCHOOLGIRL has been denied lifeline cancer therapy because NHS doctors say she’s ‘too old’ and ‘too young’. Faith Shone, 16, has leukaemia, which was caused by the heavy doses of chemotherapy she received two years ago to treat a leg tumour. Doctors say heavier doses of chemotherapy could cause her heart to fail, which […]

Teenager has to pay 70K for cancer treatment in NHS ‘blind spot’ or take offer of palliative care

In 2006, Diana Lindsay, who had never so much as held a cigarette, was diagnosed with stage 4 lung cancer. It had metastasized to both lungs, her brain and lymph nodes. Keith Eaton, MD, PhD, clinical director of thoracic, head and neck medical oncology at Fred Hutch Cancer Center, told her that a typical patient in this situation would have about nine months to live. But he also observed that she seemed remarkably strong and vital. “He said, ‘You don’t look like my normal lung cancer patient,’” said Lindsay, who had just returned from a business trip to Europe. She was 54 at the time. “He didn’t want to take away the health I had for the limited time I had to live.”

20 Years Since an EGFR Discovery, a Woman With Stage IV Lung Cancer Is Thriving

Solly Chedid, MD, provides clinical insights on quality-of-life assessment practices for patients with MDS. Case: Frontline Use of Erythroid Maturating Agent (EMA): Luspatercept. Clinical Presentation:. 70-year-old man diagnosed 6 months ago with LR-MDS with multilineage dysplasia - moderate anemia (Hb 11.2) and thrombocytosis (PLT 500,000 μl) SF3B1 mutation positive.

Assessing QoL in MDS Patients

Medical News Today

Researchers identified an enzyme that regulates glucose metabolism in the brain and discovered that a cancer drug may help treat early-stage Alzheimer's. Treatment with the cancer drug restored function in the hippocampus in an Alzheimer's mouse model.

Could a cancer drug help treat early Alzheimer’s? Study offers clues

The Independent

 Scientists are working on a “breakthrough” cancer vaccine after discovering how the body’s immune system targets cells devastated by the disease.A study led by researchers from the University of Southampton found the body’s natural “killer” cells – from the immune system which protects against disease and infections – instinctively recognise and attack a protein that drives cancer growth.The scientists believe that by using this protein – known as XPO1 – they may be able to activate more killer cells to destroy the disease, paving the way for new and less invasive forms of cancer treatment.Professor of hepatology Salim Khakoo,...

Scientists working on cancer vaccine that uses immune system’s ‘killer’ cells

Treatment with Yescarta for B-cell lymphoma may be promising within the first five years, but the risk of secondary cancers may reduce survival long term. Short-term outcomes following treatment with Yescarta (axicabtagene ciloleucel) for patients with B-cell lymphoma are reported to be promising, but long-term data regarding survivorship is still commonly unknown.

Secondary Cancers May Reduce Long-Term Survival After Yescarta in Lymphoma

Metformin, a widely-used medication for type 2 diabetes, has attracted significant attention in recent years for its potential benefits beyond blood sugar control. Research suggests that metformin may hold promise in slowing down the aging process and extending healthy lifespan. The ongoing TAME (Targeting Aging with Metformin) clinical trial is set to provide crucial evidence on whether this potential can be realized.

Unlocking Metformin’s Anti-Aging Potential: Awaiting the Groundbreaking TAME Trial Results

A drug initially developed for cancer treatment might also benefit patients suffering from Alzheimer's disease, according to a study by researchers at Penn State, Stanford University and an international team of collaborators. Researchers believe that disruption in glucose metabolism is one of the key reasons contributing to impaired brain function...

A Cancer Drug Could Restore Brain Metabolism In Alzheimer's Patients, Study Finds

When lung cancer spreads beyond the lungs, it usually first affects nearby lymph nodes. But doctors don’t usually consider lung cancer to be “metastatic” until it has spread to more distant parts of the body. Lung cancer can spread throughout the body in several ways. Cancerous cells...

Where Lung Cancer Spreads First

NewsBreak

The Promise of Gene Editing in Cancer Approaches Fruition

As gene editing technology continues to advance, it could fundamentally change the landscape of cancer treatment. A COUPLE OF DECADES ago, I was interviewing for hematology/oncology...

The Promise of Gene Editing in Cancer Approaches Fruition

Comments / 0